Autoimmune encephalitis

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Autoimmune encephalitis
Classification and external resources
ICD-10 G04.81
ICD-9-CM 323.81

Autoimmune encephalitis (or autoimmune encephalopathy) is a diverse group of neuro-psychiatric disorders recognized recently, presenting acutely or subacutely with alteration of consciousness, cognitive decline, seizure, abnormal movements. Associated with systemic autoimmune disorders, CNS autoimmune disorders and paraneoplastic syndromes. Pathogenesis is likely to be mediated by antibodies (Abs) to CNS proteins. The Abs are directed against membrane receptors and ion channel-associated proteins that are expressed on the surface of neurons in the CNS, such as N-methyl D-aspartate receptors and leucine-rich, glioma inactivated protein and contactin-associated protein like, that are associated with voltage-gated potassium channels. The diseases are not invariably cancer-related and are therefore different from the classical paraneoplastic neurological diseases that are associated with, but not caused by, Abs to intracellular proteins. Diagnosis of autoimmune encephalopathy is based on the clinical course, serologic evidence of autoimmunity, severe but nonspecific slowing on electroencephalography, and evidence of intrathecal inflammation in the cerebrospinal fluid and neuroimaging by MRI. Treatment include first-line steroids, intravenous immunoglobulins(IVIG), and plasma exchange, and second-line Rituximab and Cyclophosphamide, followed in many cases by steroid-sparing agents in the long-term.[1]

Contents

Neurological syndromes associated with autoimmune antibody (NSAAA)[edit]

Sydenham's chorea (SC)[edit]

Sydenham's chorea epidemic was first documented in 1418 and later in 1686 Thomas Sydenham described the condition.[2] The association of chorea with rheumatism was first recognized in 1802[3] and several cases has been reported by French and English workers during nineteenth century.[4] It was Richard Bright who in 1831 who first made the association between chorea and rheumatic fever. The evidence suggesting that it may be mediated by streptococcal antibodies that cross-react with the brain was published in 1993.[5]

Encephalitis lethargica (EL)[edit]

In 1916, von Economo described encephalitis lethargica (EL), a CNS disorder presenting with pharyngitis followed by sleep disorder, basal ganglia signs (particularly parkinsonism) and neuropsychiatric sequelae. Since the 1916–1927 epidemic, only sporadic cases have been described. Pathological studies revealed an encephalitis of the midbrain and basal ganglia, with lymphocyte (predominantly plasma cell) infiltration. The EL epidemic occurred during the same time period as the 1918 influenza pandemic, and the two outbreaks have been linked in the medical literature. However, von Economo and other contemporary scientists thought that the 1918 influenza virus was not the cause of EL. Recent examination of archived EL brain material has failed to demonstrate influenza RNA, adding to the evidence that EL was not an invasive influenza encephalitis. By contrast, the findings of intrathecal oligoclonal bands (OCB) and beneficial effects of steroid treatments have provoked the hypothesis that EL may be immune‐mediated.[6][7]

Hashimoto's encephalopathy[edit]

In 1966 Brain et al. described a 49-year-old man with Hashimoto's thyroiditis who presented with stroke-like episodes and subsequently delirium. The patient did not respond to prednisone, but eventually recovered, leading Brain to suggest that autoimmune mechanisms might be responsible. Since that time, there have been many further cases reported in the literature of Hashimoto's encephalopathy.[8] The term Hashimoto's encephalopathy is used to describe an encephalopathy of presumed autoimmune origin characterized by high titres of antithyroid peroxidase antibodies. Hashimoto's encephalopathy is more common in women than in men. It has been reported in paediatric, adult and elderly populations throughout the world. The clinical presentation may involve a relapsing and remitting course and include seizures, stroke-like episodes, cognitive decline, neuropsychiatric symptoms and myoclonus. Thyroid function is usually clinically and biochemically normal. It is likely that antithyroid antibodies are not pathogenic, but titres can be a marker of treatment response. Pathological findings can suggest an inflammatory process, but features of a severe vasculitis are often absent.[9]

Steroid-responsive nonvasculitic autoimmune inflammatory meningoencephalitic syndrome[edit]

Caselli RJ in 1999 reported five patients, age 54 to 80 years, presented between 3 weeks and 18 months after symptomatic onset of progressive cognitive decline, psychosis, and unsteady gait that proved to be due to a steroid-responsive nonvasculitic autoimmune inflammatory meningoencephalitic syndrome.[10]

Limbic encephalitis (LE)[edit]

The term limbic encephalitis (LE) was originally coined by Corsellis in 1968,[11] present with the subacute onset of episodic memory impairment, disorientation and agitation, commonly associated with seizures, hallucinations, sleep disturbance and histological evidence of medial temporal lobe inflammation.[12] Signal changes in the medial temporal lobes or hippocampi are frequently found on MRI.[13] Its association with lung cancer and Hu antibody, Ma2 with testicular tumors and CRMP5/CV2 in patients with thymomas. Anti-NMDA-receptor encephalitis and its association with teratoma was published in 2008 by Josep Dalmau.[14] There may be improvement after treatment of the primary tumor, but in general the prognosis of paraneoplastic limbic encephalitis is poor.[11] A few cases of non‐paraneoplastic limbic encephalitis have been described.[13]

Paraneoplastic limbic encephalitis (PLE)[edit]

Paraneoplastic limbic encephalitis (PLE) is a disorder characterized by personality changes, irritability, depression, seizures, memory loss and sometimes dementia. The diagnosis of PLE required neuropathological examination or the presence of the four following criteria: (i) a compatible clinical picture; (ii) an interval of <4 years between the development of neurological symptoms and tumour diagnosis; (iii) exclusion of other neuro-oncological complications; and (iv) at least one of the following: CSF with inflammatory changes but negative cytology; MRI demonstrating temporal lobe abnormalities; EEG showing epileptic activity in the temporal lobes.[15]

Table

Paraneoplastic antibodies associated with limbic encephalitis[14][16][17]

Antibody Syndrome Cancer
Hu Limbic encephalitis, encephalomyelitis SCLC, other
Ma2 Limbic, hypothalamic,a and brainstem encephalitis Testis, lung, other
CV2/CRMP5 Limbic, striatal encephalitis (chorea), cerebellar ataxia, peripheral neuropathy, uveitis SCLC, thymoma
Amphiphysin Limbic encephalitis, stiff-person syndrome Breast, SCLC
NMDA Limbic encephalitis, Teratoma of ovary
Anti-AMPAR Limbic encephalitis Lung, thymoma, breast, ovarian teratoma

Non paraneoplastic limbic encephalitis (NPLE)[edit]

History[edit]

Mori M in 2002 reported a 21-year-old woman subacutely developed memory loss subsequent to gastroenteritis. Brain MRI with gadolinium enhancement showed symmetric involvement of the amygdala. The CSF was acellular with increased protein level. There was no evidence suggestive of neoplasm or viral infection. Combined treatment with plasmapheresis and immunoglobulin improved her clinical symptoms and lessened abnormalities manifested in the MRI. He suggested the presence of immune-mediated limbic encephalitis without association with neoplasms or infections.[18] Similar case in an elderly man was presented with steroid response in 2003.[19][20] Subacute onset partial seizures with recent memory and no evidence of underlying malignancy was recognized as limbic encephalitis unrelated to neoplasm.[21][22]

Clinical features[13][edit]

Age: Children,[23][24] Young Adult,[25] Elderly[19]

Sex: Both

Onset: Subacute

Clinical features NMDA Ab related patients in adult shows;[26]

  • Early features of higher cognitive dysfunction, confusion, behavioural changes, amnesia, dysphasia. Psychiatric: hallucinations, psychotic, agitation, depressive, anxiety, obsessive. Seizures: generalized, complex partial, simple partial.
  • Late features: Spontaneous reduction in conscious level, Movement disorder: choreoathetoid (orofacial, upper limbs, lower limbs), parkinsonian, rigidity, myoclonus, oculogyric crises, opisthotonus, startle. Dysautonomia : tachy/brady-cardia, hyperhidrosis, persistent pyrexia, central hypoventilation, labile/high blood pressure, hypersalivation, pseudoobstruction, cardiac asystole.

NMDA Ab related patients in children and adolescent.[25]

Commonly

  • Behavioral or personality change, sometimes associated with
  • Seizures and
  • Sleep dysfunction;
  • Severe speech deficits on admission
  • Stereotyped movements,
  • Autonomic instability
  • Hypoventilation

Rarely

  • Dyskinesias or dystonia;

Other Cases have similar presentation

Diagnosis[edit]
Antibody test in serum and CSF[edit]
  1. Voltage-gated potassium channel antibodies (VGKC‐Abs)[31][32][33][33][34]
  2. GluRepsilon2 (NR2B)[35]
  3. Glutamic acid decarboxylase (GAD).[36][37]
  4. Anti-NMDAR Ab[26][38] most common in children unrelated to tumor.[25]
Neuro imaging[edit]

MRI: medial temporal lobe signal change[13] bilateral hippocampal lesions, with signals that were hypointense in IR sequences and hyperintense in FLAIR.[20]

Treatment[edit]

Immunotherapy with steroid and plasmapheresis, IVIG.

Prognosis[edit]

Variable following immunotherapy with partial to excellent recovery.[28][39]

Chronic sequelae due to hippocampal sclerosis and chronic epilepsy is also reported.[27]

Post herpes simplex NMDA antibody encephalitis[edit]

Some children and adults with herpes simplex virus (HSV) encephalitis and subsequent relapses characterized by choreoathetosis in children and behavioral/psychiatric features in adults were found to have NMDAR Abs without HSV reactivation, they improved with immunotherapy.[40][41][42][43]

Morvan's syndrome[edit]

History[edit]

In 1890, Morvan described a patient with myokymia (muscle twitching) associated with muscle pain, excessive sweating and disordered sleep Morvan's fibrillary chorea (MFC).[44] The course was severe and the patient died 5 weeks after onset. A similar condition characterized by widespread myokymia and cramping, but without overt CNS involvement has since been described and is now referred to as Isaacs' syndrome (1961)[45] and neuromyotonia (NMT) in 1965.[46] Acquired NMT is thought to be autoimmune in a high proportion of cases. It can be associated with thymoma,[47] and antibodies to voltage-gated K+ channels (VGKCs) are present in a proportion of patients.[13][48][49] Although anti-VGKC antibody negative cases of Morvan's syndrome have been reported in the literature, it is possible that, in these cases, the antigenic components are yet to be formally identified.[50]

Pathogenesis[edit]

Mice injected with NMT immunoglobulins have prolonged neuronal action potentials and increased neurotransmitter release.[48] MFC, or Morvan's syndrome,[51] is NMT with overt CNS involvement. It is probably also autoantibody-mediated [52][53][54][55][56] but the nature of the CNS dysfunction and the targets for the antibodies are not clear.[17]

In brain tissue regions including the hypothalamus, raphe, and locus coeruleus, commercial antibodies to LGI1 bound to neuronal cell bodies including the antidiuretic hormone-secreting and orexin-secreting hypothalamic neurons, whereas CASPR2 commercial antibodies bound more often to the neuropil. MoS antibodies bound similarly, but there was evidence of additional antibodies in some sera that were not adsorbed by LGI1- or CASPR2-expressing cells and bound to mouse Caspr2(-/-) tissue.[57]

Clinical features[57][edit]

  • Male (93%)
  • Neuromyotonia (100%),
  • Neuropsychiatric features (insomnia 89.7%, confusion 65.5%, amnesia 55.6%, hallucinations 51.9%),
  • Dysautonomia (hyperhidrosis 86.2%, cardiovascular 48.3%),
  • Neuropathic pain (62.1%)
  • Associated tumors thymoma in (41.4%),

Investigation[edit]

MRI Brain: shows only evidence of small vessel disease,[50] and normal in 92% of patients.[57]

EEG: Nonspecific slow wave abnormality. Polysomnography shows complete absence of sleep.[58]

Antigenic Source: VGKC-complex antibodies were present in 23 of 29 (79%), CASPR2, LGI1 antibodies, or both, CASPR2 antibodies were generally higher titer than LGI1 antibodies and associated with thymoma. LGI1 antibodies were associated with serum hyponatremia.[57]

Treatment[edit]

Immunosuppressive therapies, encompassing corticosteroids, azathioprine, methotrexate and more recently, rituximab, are the mainstay of therapy.[59] Other treatments include PE, IVIG, and thymectomy. Patients reportedly exhibited a heterogenous response to immunomodulation.[50]

Antiepileptics can be used for symptomatic relief of peripheral nerve hyperexcitability. Indeed, some patients have exhibited a spontaneous remission of symptoms.[50]

Prognosis[edit]

Prognosis is poor, however, current analysis suggests that those associated with thymoma, benign or malignant, show a less favorable prognosis (CASPR2 Ab positive).[57]

Autoimmune antibodies associated neurological syndromes (AAANS)[edit]

N-Methyl D-aspartate receptor (NMDAR, NR1, NR2)[edit]

N-Methyl D-aspartate receptor (NMDAR) Ab encephalitis is the most common Ab-mediated autoimmune encephalopathy.[60] It was first described in 2005 as a paraneoplastic syndrome associated with ovarian teratomas in young women[61] and the antigenic target was determined in 2007,[62] associated with antibodies against NR1 or NR2 subunits of the NMDA receptor.[63] Irani et al. in 2010 presented NMDAR Ab encephalitis in a predominantly non-paraneoplastic disorder of both sexes.[26]

Epidemiology[edit]

Most common cause of autoimmune encephalitis after acute demyelinating encephalitis in England.[64] More than 500 cases have been reported in literature till 2013.[63] In California Encephalitis Project it was found >4 times as frequently as herpes simplex virus type 1 (HSV-1), varicella-zoster virus (VZV), and West Nile virus (WNV).[65] Among patients with first-onset schizophrenia incidence varies between 6–10%.[66][67]

  • Age – frequently 5–76 years, Median age of patients was 23 years
  • Sex – 80% Female

Clinical features[edit]

Prodrome[edit]

About 70% of patients have prodromal symptoms consisting of headache, fever, nausea, vomiting, diarrhoea, or upper respiratory-tract symptoms.[68]

Syndrome[edit]

Within a few days, usually less than 2 weeks patients develop

  • Behavioral disturbance: agitation
  • Auditory and visual hallucinations,
  • Delusions
  • Psychosis
  • Amnesia,
  • Seizures,
  • Dyskinesias, Catatonia, orolingual dyskinesias and stereotypic movement
  • Autonomic dysfunction, and
  • Decreased level of consciousness often requiring ventilatory support.[14][63][68]

Antibody[edit]

The main epitope targeted by the antibodies is in the extracellular N-terminal domain of the NR1 subunit.[14] All had serum/cerebrospinal fluid antibodies that predominantly immunolabeled the neuropil of hippocampus/forebrain, in particular the cell surface of hippocampal neurons, and reacted with NR2B (and to a lesser extent NR2A) subunits of the NMDAR. NR2B binds glutamate and forms heteromers (NR1/NR2B or NR1/NR2A/NR2B) that are preferentially expressed in the adult hippocampus/forebrain[62]

Tumor associated[edit]

Ovarian teratoma

Treatment[edit]

Treatment included first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line immunotherapy (rituximab, cyclophosphamide), and tumour removal.[69]

Prognosis[edit]

Most patients recovered or had mild deficits and some had severe deficits or died.It may take up to 18 months for improvement was associated with a decrease of serum antibody titres.[69] Untreated patients had high mortality (25%).[14][63]

Voltage-gated potassium channel antibody syndromes[edit]

The voltage-gated potassium channel (VGKC) complex Abs are the second most commonly identified Abs in CNS Ab-mediated diseases, but the clinical spectrum and treatment responses are very different from those of the NMDAR Ab encephalitis. The clinical spectrum includes both central and peripheral nervous system disorders.

History[edit]

VGKC complex Abs were first described in association with neuromytonia (NMT) or Isaac's syndrome.[45][70] VGKC complex Abs were found in around 40% of patients with NMT and then more frequently and at higher levels in patients with NMT associated with dysautonomia and CNS disturbance including insomnia and limbic dysfunction, which is usually called Morvan's syndrome (MoS),[17][57] and in a form of nonparaneoplastic limbic encephalitis (LE). Although these Abs were initially identified by immunoprecipitation of radioactive dendrotoxin-labeled VGKCs in digitonin-solubilized mammalian brain homogenates, further evidence indicated that they bind to protein components of the VGKC complex rather than to the VGKC itself; their identification requires Ag-specific cell-based assays.[71][72]

Pathogenesis[edit]

The VGKC complex is composed of Kv1 subunits and other proteins that are tightly complexed with the Kv1 subunits in the nerve membrane. They are widely expressed in the nervous system, particularly at the juxtaparanodes of the nodes of Ranvier, at peripheral motor nerve, and perhaps sensory terminals, and in central synapses. Because opening of the VGKC following each action potential leads to repolarization of the membrane, VGKCs regulate neuronal activity throughout the nervous system.

In some patients VGKC Abs are detected by radioimmunoassay, in the absence of LGI1, CASPR2, or contactin 2 Ab specificity. In general, high titers (usually > 400 pM) are more frequently associated with defined clinical phenotypes (mainly LE, but also peripheral nerve hyperexcitability (PNH), seizures, or MoS), whereas low titers of Abs can be found in patients with either or both CNS and PNS syndromes but are also detected in patients without a clear immune-mediated phenotype.[73][74][75] It is possible, that in these cases, the Abs bind to intracellular targets on the solubilized VGKC complex.

Potassium channel KIR4 (.Dipeptidyl-peptidase-like Protein-6) is a protein associated with another VGKC, Kv4, that is responsible for regulating firing rates of action potentials in dendrites in the central and peripheral nervous system.[75]

VGKC antibodies spectrum[75][edit]

  1. The main targets for the Abs are LGI1, typically associated with LE, and a specific focal epilepsy, faciobrachial dystonic seizures (FBDS). In around 20–40 % of patients with LGI1 Abs a specific seizure type can precede the occurrence of full-blown LE.[76] These events have been described as "tonic seizures",[77] or FBDS,[76] and consist of brief and very frequent involuntary movement with dystonic features involving mainly the arm, the ipsilateral side of the face, and, less frequently, the leg. The response to routinely used anticonvulsant drugs is usually poor, but a dramatic reduction or complete resolution of the FBDS can be obtained with oral steroids.[78] Irani et al.[76] described a prospective cohort of 10 patients with FBDS, where the development of cognitive impairment was only present in patients who did not receive immunotherapy, suggesting that early treatment can result in a better recovery and sometimes prevent progression to encephalopathy.
  2. Contactin-associated protein like (CASPR2), associated with a broader spectrum of central and peripheral nervous system disorders such as LE, NMT, or a combination of the two (MoS).
  3. A third antigen, contactin 2, has been identified, usually in patients with concomitant anti-LGI1 or anti-CASPR2 Abs and with no specific phenotype, suggesting an unclear clinical relevance.
  4. Potassium channel (KIR4.1) Abs to dipeptidyl-peptidase-like protein-6 were initially identified in patients with a form of LE associated with gastrointestinal dysmotility (due to the involvement of the myoenteric plexus), sleep disturbances, cognitive and psychiatric manifestations, and dysautonomic features,[79] and subsequently in a disease presenting with hyperekplexia, trunk rigidity, and cerebellar ataxia[1][80]

Clinical features[13][81][edit]

Age: Adult and Elderly

Sex: Both

Onset : Subacute

Behavior change

Memory loss, confabulation

Confusion and disorientation

Hallucinations

Dyssomnia

Seizures focal and generalized, myoclonic

Extrapyramidal dysfunction

Brainstem/cranial nerve dysfunction

Dysautonomia

Neuromyotonia

Peripheral nerve dysfunction

Hyponatreamia

Investigation[13][edit]

MRI Brain: Medial temporal T2 hyperintense signal changes in most cases.[13] and atrophy on followup.

CSF: Mild pleocytosis and raised proteins and negative HSV.

Antibody: Elevated VGKC-Abs in CSF and Serum

EEG: Nonspecific background slowing and frontotemporal sharp waves.

Associated Tumors: 18 carcinomas, 5 adenomas, 1 thymoma, and 3 hematologic malignancies.[81]

Associated autoimmune disease: thyroiditis 21%, type 1 diabetes mellitus 11%.[81]

Treatment[edit]

Immunotherapy : Steroid, Plasmapheresis, IVIG.[13][81]

Prognosis[edit]

Delayed recovery with immunotherapy.[13] Marked recovery in 50%.[81]

AMPAR (GluR1, GluR2) antibody syndrome[edit]

Anti–α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)are a subgroup of ionotropic glutamate receptor mainly present in excitatory synapses of the CNS. Abs against the extracellular domains of AMPA subunits GluR1 and GluR2 were associated originally with a particularly aggressive form of LE, often accompanied by the presence of a tumor.[82]

Clinical features[83][edit]

  • Age: Median age was 62 years (range 23–81; 14 female)
  • Common
    • Limbic encephalitis (LE),12 (55%)
    • Limbic dysfunction along with multifocal/diffuse encephalopathy, 8 (36%)
  • Rare
    • LE preceded by motor deficits
    • Psychosis with bipolar features.

Associated turmors: lung, thymoma, breast, ovarian teratoma (64%)

Treatment[edit]

Immunotherapy with steroid, relapse rituximab and/or cyclophosphamyde.

Prognosis[edit]

5 had good response to immunotherapy and tumor therapy, 10 partial response, and 6 did not improve. Eventually 5 patients died; all had a tumor or additional paraneoplastic symptoms related to onconeuronal antibodies. Coexistence of onconeuronal antibodies predicted a poor outcome.[17]

Glycine receptor antibody syndrome[edit]

Pathogenesis: Abs directed against the α1 subunit of the glycine receptor (GlyR)

Clinical features[edit]

Variants of stiff person syndrome

  • progressive encephalomyelitis,
  • Rigidity,
  • Myoclonus, stimulus-sensitive spasms, hyperekplexia,
  • Autonomic disturbances, and
  • Brainstem disorders.[84]
  • Isolated optic neuritis
  • Focal seizure in adult[85]

Diagnosis[edit]

Treatment[edit]

Acombination of IVMP, PLEX, and IVIg followed by oral prednisolone.[86] Relapsed required prolonged immunosuppression with MMF, AZA, or cyclophosphamide.[85]

Prognosis[edit]

Improves with immunotherapy and complete resolution of clinical symptoms.

Dopamine 2 receptor antibody syndrome (D2RA)[edit]

History[edit]

Sydenham's chorea is the foremost classic autoimmune basal ganglia disorder.[87] Possible autoimmune mechanism for encephalitis lethargica with Parkinsonian syndrome has been suggested.[6] The evidence for an autoimmune disorder is less clear for paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS).[88] An autoimmune subgroup may exist in Tourette's syndrome, although results remain controversial.[89] Autoimmune movement disorder with basal ganglia encephalitis associated with D2RA have found recently.[90]

Pathogenesis[edit]

D1- and D2-class receptors have high expression in basal ganglia, for example striatum (caudate–putamen), but also in cortex, hippocampus and substantia nigra. Modulation of D2R expression in the basal ganglia has been associated with schizophrenia, depression and movement disorders.[91] D2R is intimately linked to the control of movement and behavior e.g. myoclonus dystonia is associated with D2R gene mutations.[92] Movement and psychiatric disorders associated with D2R antibody are biologically plausible as D2R is intimately linked to the control of movement and behavior.[90]

Clinical features[90][edit]

Movement Disorder

  • Dystonia
  • Parkinsonism
  • Chorea
  • Ocular flutter
  • Motor tics

Psychiatric Symptoms

  • Agitation
  • Emotional lability
  • Psychosis
  • Depression

Associated symptoms

  • Encephalopathy
  • Sleep disorder
  • Reduced consciousness
  • Mutism

Diagnosis[90][edit]

Based on syndrome with focal or diffuse neurological dysfunction associated with fever. Inflammatory lesion in MRI and CSF pleocytosis. EEG signs of encephalitis.

Treatment[edit]

Immunotherapy

Prognosis[edit]

Commonly monophasic illness, few had relapse after improvement.[90] Persistent neurological deficit were recorded before immunotherapy was given in historical cases.[1]

GABA receptor Ab syndrome[edit]

History[edit]

High titres of serum and CSF GABAA receptor antibodies are associated with a severe form of encephalitis with seizures, refractory status epilepticus, or both.[93] Another paper described 40 patients with Abs of the IgG and IgM subclasses targeting the α1 and γ2 subunits of the GABAA receptor.[94]

GABABR is a protein widely distributed in the brain and located both pre- and postsynaptically. Genetic alterations of the receptor are associated with epilepsy and cognitive impairment, and Abs against the B1 subunit are found in patients with LE and, rarely, ataxia, 50% of whom will have a small-cell lung carcinoma.[95] Encephalitis associated with anti-γ-aminobutyric acid-B (GABAB) receptor antibodies has been identified recently.[96]

Clinical features[edit]

GABAb Ab syndrome has a clinical triad of confusion, memory changes, seizure,[96] Rarely ataxia, status epilepticus and opsoclonus-myoclonus syndrome (OMS).[97]

GABAa Ab syndrome has most common presenting features were seizures (47%), memory impairment (47%) with confusion or disorientation (27%), or psychiatric features (33%) with hallucinations (33%) or anxiety (27%).[94] Refractory status epilepticus.[93]

Tumor association[edit]

  • Lymphoma in few cases of GABAa Ab syndrome[94]
  • Small-cell lung cancer in 50% of GABAb Ab syndrome.[97]

Diagnosis[edit]

MRI were normal or nonspecific in most cases.[94]

CSF examination was also not informative.[94]

Treatment[edit]

The administration of immunotherapy, in association with chemotherapy or tumor removal, .[94][96]

Prognosis[edit]

A complete recovery following immunotherapy and tumor removal. Untreated cases died within few months of onset. Some patients have a poor outcome despite sustained immunosuppression, but that is often related to tumor progression or associated with the presence of Abs directed against intracellular Ags such as GAD Abs or amphyphysin Abs, which can reflect the involvement of an additional cytotoxic T-cell mechanism in the progression of the disease.[97]

Metabotropic glutamate receptor antibody syndrome[edit]

Metabotropic glutamate receptors belong to a large family of cell-surface receptors that transmit signals into the cell by coupling to guanine nucleotide-binding proteins (G proteins) in the cytoplasm.

Subacute cerebellar ataxia[edit]

Metabotropic glutamate receptor type 1 Ab (mGluR1) syndromes are rare and recently described associated with few cases with subacute cerebellar ataxia associated with Hodgkin's lymphoma in 2000.[98]

Subsequently a non paraneoplastic syndrome, was described and the disease was stabilized after a course of intravenous immunoglobulins and continuous mycophenolate mofetil treatment during a follow-up of 40 months.[99]

Ophelia syndrome[edit]

More recently (2011), Abs directed to the mGluR5 Abs were identified in 2 patients with limbic encephalopathy and Hodgkin's lymphoma, a combination known as Ophelia syndrome.[100] Hippocampus neuron mGluR5, a receptor involved in processes of learning and memory.[101]

Ophelia syndrome was characterized by

  1. the epitopes are in the extracellular domain of the receptor, as shown by patients' antibody binding to the surface of live neurons;
  2. the antibodies specifically react with mGluR5, as demonstrated by the abrogation of reactivity with brain of mGluR5-null mice and lack of cross-reactivity with mGluR1; and
  3. the neurologic disorder is reversible.[101]

In both cases prompt tumor treatment (excision or chemotherapy) was performed, and 1 patient also received steroids, resulting in complete regression of the symptoms.

IgLON5 Ab syndrome[102][edit]

In 2014, a novel syndrome with sleep disorders (parasomnia and breathing dysfunction), gait instability, and brainstem symptoms was described in 8 patients in association with surface Abs to the neuronal cell adhesion protein IgLON5. Neuropathological investigations in 2 patients identified tau aggregates in the tegmentum of the brainstem and in the hypothalamus that could not be classified within any known tauopathy, suggesting a possible neurodegenerative etiology of the disease. Moreover, despite immunosuppressive treatments including steroids, IVIg, cyclophosphamide, and rituximab, only 1 patient showed some improvement. Whether the Abs are a primary or secondary element in the disease development needs to be clarified.

See also[edit]

References[edit]

  1. ^ a b c Gastaldi, Matteo; Thouin, Anaïs; Vincent, Angela (2016-01-01). "Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies". Neurotherapeutics. 13 (1): 147–162. ISSN 1878-7479. PMC 4720680Freely accessible. PMID 26692392. doi:10.1007/s13311-015-0410-6. 
  2. ^ Van der Merwe, PL (1997). "Sydenham's chorea--analysis of 27 patients and a review of the literature". S Afr Med J. 87 (Suppl 3): C157–60. PMID 9254767. 
  3. ^ Bright, R (1838). "Cases of spasmodic disease accompanying affections of the pericardium.". Trans Med-Chir Soc London. 
  4. ^ Martino, D.; Tanner, A.; Defazio, G.; Church, A. J.; Bhatia, K. P.; Giovannoni, G.; Dale, R. C. (2005-05-01). "Tracing Sydenham's chorea: historical documents from a British paediatric hospital". Archives of Disease in Childhood. 90 (5): 507–511. ISSN 1468-2044. PMC 1720385Freely accessible. PMID 15851434. doi:10.1136/adc.2004.057679. 
  5. ^ Bronze, MS (1993). "Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain". J. Immunol. 151 (5): 2820–8. PMID 7689617. 
  6. ^ a b Dale, Russell C.; Church, Andrew J.; Surtees, Robert A. H.; Lees, Andrew J.; Adcock, Jane E.; Harding, Brian; Neville, Brian G. R.; Giovannoni, Gavin (2004-01-01). "Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity". Brain. 127 (Pt 1): 21–33. ISSN 0006-8950. PMID 14570817. doi:10.1093/brain/awh008. 
  7. ^ Reid, A. H.; McCall, S.; Henry, J. M.; Taubenberger, J. K. (2001-07-01). "Experimenting on the past: the enigma of von Economo's encephalitis lethargica". Journal of Neuropathology and Experimental Neurology. 60 (7): 663–670. ISSN 0022-3069. PMID 11444794. doi:10.1093/jnen/60.7.663. 
  8. ^ Brain, L (1966). "Hashimoto's disease and encephalopathy". Lancet. 2 (7462): 512–4. PMID 4161638. doi:10.1016/s0140-6736(66)92876-5. 
  9. ^ Mocellin, Ramon; Walterfang, Mark; Velakoulis, Dennis (2007-01-01). "Hashimoto's encephalopathy : epidemiology, pathogenesis and management". CNS Drugs. 21 (10): 799–811. ISSN 1172-7047. PMID 17850170. doi:10.2165/00023210-200721100-00002. 
  10. ^ Solimena, M (1988). "Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus". N Engl J Med. 318 (16): 1012–20. PMID 3281011. doi:10.1056/NEJM198804213181602. 
  11. ^ a b Corsellis, JA (1968). "Limbic encephalitis" and its association with carcinoma". Brain. 91 (3): 481–96. PMID 5723018. doi:10.1093/brain/91.3.481. 
  12. ^ Brierley, JB (1960). "Subacute encephalitis of later adult life. Mainly affecting the limbic areas". Brain. 
  13. ^ a b c d e f g h i j Vincent, Angela; Buckley, Camilla; Schott, Jonathan M.; Baker, Ian; Dewar, Bonnie-Kate; Detert, Niels; Clover, Linda; Parkinson, Abigail; Bien, Christian G. (2004-03-01). "Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis". Brain. 127 (Pt 3): 701–712. ISSN 0006-8950. PMID 14960497. doi:10.1093/brain/awh077. 
  14. ^ a b c d e Dalmau, Josep; Gleichman, Amy J.; Hughes, Ethan G.; Rossi, Jeffrey E.; Peng, Xiaoyu; Lai, Meizan; Dessain, Scott K.; Rosenfeld, Myrna R.; Balice-Gordon, Rita (2008-12-01). "Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies". The Lancet. Neurology. 7 (12): 1091–1098. ISSN 1474-4422. PMC 2607118Freely accessible. PMID 18851928. doi:10.1016/S1474-4422(08)70224-2. 
  15. ^ Gultekin, Humayun (2000). "Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients". Brain. 123 (Pt 7): 1481–94. PMID 10869059. doi:10.1093/brain/123.7.1481. 
  16. ^ Dalmau, Josep; Bataller, Luis (2006-12-01). "Clinical and Immunological Diversity of Limbic Encephalitis: A Model for Paraneoplastic Neurologic Disorders". Hematology/Oncology Clinics of North America. 20 (6): 1319–1335. ISSN 0889-8588. PMC 1920176Freely accessible. PMID 17113466. doi:10.1016/j.hoc.2006.09.011. 
  17. ^ a b c d Liguori, R.; Vincent, A.; Clover, L.; Avoni, P.; Plazzi, G.; Cortelli, P.; Baruzzi, A.; Carey, T.; Gambetti, P. (2001-12-01). "Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels". Brain. 124 (Pt 12): 2417–2426. ISSN 0006-8950. PMID 11701596. doi:10.1093/brain/124.12.2417. 
  18. ^ Mori, Masahiro; Kuwabara, Satoshi; Yoshiyama, Mitsuharu; Kanesaka, Toshihide; Ogata, Tsuyoshi; Hattori, Takamichi (2002-09-15). "Successful immune treatment for non-paraneoplastic limbic encephalitis". Journal of the Neurological Sciences. 201 (1–2): 85–88. ISSN 0022-510X. PMID 12163199. doi:10.1016/s0022-510x(02)00188-0. 
  19. ^ a b Watanabe, Yasuhiro; Shimizu, Yasutaka; Ooi, Shinji; Tanaka, Keiko; Inuzuka, Takashi; Nakashima, Kenji (2003-05-01). "Steroid-responsive limbic encephalitis". Internal Medicine. 42 (5): 428–432. ISSN 0918-2918. PMID 12793715. doi:10.2169/internalmedicine.42.428. 
  20. ^ a b Lang, Pierre Olivier; Sellal, François (2008-05-01). "[Non-paraneoplastic limbic encephalitis revealed by anterograde amnesia]". Presse Médicale. 37 (5 Pt 1): 775–782. ISSN 0755-4982. PMID 18261871. doi:10.1016/j.lpm.2007.11.013. 
  21. ^ a b Prats-Viñas, J. M.; Gaztañaga-Expósito, R.; Palacio-Pina, M. (2003-02-15). "[Non-paraneoplastic limbic encephalitis]". Revista De Neurologia. 36 (4): 335–337. ISSN 0210-0010. PMID 12599129. 
  22. ^ a b Vincent, Angela; Bien, Christian G. (2005-09-01). "Temporal lobe seizures, amnesia and autoantibodies - identifying a potentially reversible form of non-paraneoplastic limbic encephalitis". Epileptic Disorders. 7 (3): 177–179. ISSN 1294-9361. PMID 16162425. 
  23. ^ Dubey, Divyanshu; Sawhney, Anshudha; Greenberg, Benjamin; Lowden, Andrea; Warnack, Worthy; Khemani, Pravin; Stuve, Olaf; Vernino, Steven (2015-10-15). "The spectrum of autoimmune encephalopathies". Journal of Neuroimmunology. 287: 93–97. ISSN 1872-8421. PMID 26439968. doi:10.1016/j.jneuroim.2015.08.014. 
  24. ^ Kröll-Seger, Judith; Bien, Christian G.; Huppertz, Hans-Jürgen (2009-03-01). "Non-paraneoplastic limbic encephalitis associated with antibodies to potassium channels leading to bilateral hippocampal sclerosis in a pre-pubertal girl". Epileptic Disorders. 11 (1): 54–59. ISSN 1294-9361. PMID 19251579. doi:10.1684/epd.2009.0237 (inactive 2017-01-31). 
  25. ^ a b c Florance, Nicole R.; Davis, Rebecca L.; Lam, Christopher; Szperka, Christina; Zhou, Lei; Ahmad, Saba; Campen, Cynthia J.; Moss, Heather; Peter, Nadja (2009-07-01). "Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents". Annals of Neurology. 66 (1): 11–18. ISSN 1531-8249. PMC 2826225Freely accessible. PMID 19670433. doi:10.1002/ana.21756. 
  26. ^ a b c Irani, Sarosh R.; Bera, Katarzyna; Waters, Patrick; Zuliani, Luigi; Maxwell, Susan; Zandi, Michael S.; Friese, Manuel A.; Galea, Ian; Kullmann, Dimitri M. (2010-06-01). "N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes". Brain. 133 (6): 1655–1667. ISSN 0006-8950. PMC 2877907Freely accessible. PMID 20511282. doi:10.1093/brain/awq113. 
  27. ^ a b Wieser, Stephan; Kelemen, Anna; Barsi, Peter; Vincent, Angela; Borbely, Csaba; Rasonyi, Gyorgy; Mueller, Susanne; Hess, Klaus; Wieser, Heinz Gregor (2005-09-01). "Pilomotor seizures and status in non-paraneoplastic limbic encephalitis". Epileptic Disorders. 7 (3): 205–211. ISSN 1294-9361. PMID 16162429. 
  28. ^ a b Kondziella, Daniel; Andersen, Oluf; Asztely, Fredrik; Holmberg, Björn; Hedström, Anders; Szentgyörgyi, Eva (2008-03-01). "Excellent outcome after prolonged status epilepticus due to non-paraneoplastic limbic encephalitis". Acta Neurologica Belgica. 108 (1): 21–23. ISSN 0300-9009. PMID 18575183. 
  29. ^ Gotkine, Marc; Ben-Hur, Tamir; Vincent, Angela; Vaknin-Dembinsky, Adi (2011-09-15). "Limbic encephalitis presenting as a post-partum psychiatric condition". Journal of the Neurological Sciences. 308 (1–2): 152–154. ISSN 1878-5883. PMID 21705029. doi:10.1016/j.jns.2011.06.017. 
  30. ^ Dale, Russell C.; Irani, Sarosh R.; Brilot, Fabienne; Pillai, Sekhar; Webster, Richard; Gill, Deepak; Lang, Bethan; Vincent, Angela (2009-11-01). "N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica". Annals of Neurology. 66 (5): 704–709. ISSN 1531-8249. PMID 19938173. doi:10.1002/ana.21807. 
  31. ^ Buckley, C.; Oger, J.; Clover, L.; Tüzün, E.; Carpenter, K.; Jackson, M.; Vincent, A. (2001-07-01). "Potassium channel antibodies in two patients with reversible limbic encephalitis". Annals of Neurology. 50 (1): 73–78. ISSN 0364-5134. PMID 11456313. doi:10.1002/ana.1097. 
  32. ^ Schott, J. M.; Harkness, K.; Barnes, J.; della Rocchetta, A. Incisa; Vincent, A.; Rossor, M. N. (2003-04-12). "Amnesia, cerebral atrophy, and autoimmunity". Lancet. 361 (9365): 1266. ISSN 0140-6736. PMID 12699955. doi:10.1016/s0140-6736(03)12983-2. 
  33. ^ a b Samarasekera, S. R.; Vincent, A.; Welch, J. L.; Jackson, M.; Nichols, P.; Griffiths, T. D. (2007-04-01). "Course and outcome of acute limbic encephalitis with negative voltage-gated potassium channel antibodies". Journal of Neurology, Neurosurgery, and Psychiatry. 78 (4): 391–394. ISSN 1468-330X. PMC 2077800Freely accessible. PMID 17098840. doi:10.1136/jnnp.2006.093096. 
  34. ^ Pozo-Rosich, Patricia; Clover, Linda; Saiz, Albert; Vincent, Angela; Graus, Francesc (2003-10-01). "Voltage-gated potassium channel antibodies in limbic encephalitis". Annals of Neurology. 54 (4): 530–533. ISSN 0364-5134. PMID 14520669. doi:10.1002/ana.10713. 
  35. ^ Takahashi, Yukitoshi; Mogami, Yukiko; Takayama, Rumiko; Ikeda, Hiroko; Imai, Katsumi (2010-08-01). "[Antibodies to glutamate receptor in limbic encephalitis]". Brain and Nerve = Shinkei Kenkyū No Shinpo. 62 (8): 827–837. ISSN 1881-6096. PMID 20714031. 
  36. ^ Matà, Sabrina; Muscas, Gian Carlo; Naldi, Ilaria; Rosati, Eleonora; Paladini, Sergio; Cruciatti, Barbara; Bisulli, Francesca; Paganini, Marco; Mazzi, Gustavo (2008-08-13). "Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies". Journal of Neuroimmunology. 199 (1–2): 155–159. ISSN 0165-5728. PMID 18586329. doi:10.1016/j.jneuroim.2008.05.015. 
  37. ^ Cianci, Vittoria; Labate, Angelo; Lanza, Pierluigi; Vincent, Angela; Gambardella, Antonio; Branca, Damiano; Arcudi, Luciano; Aguglia, Umberto (2010-09-01). "Non-paraneoplastic limbic encephalitis characterized by mesio-temporal seizures and extratemporal lesions: a case report". Seizure. 19 (7): 446–449. ISSN 1532-2688. PMID 20598587. doi:10.1016/j.seizure.2010.06.002. 
  38. ^ Kramina, Sandra; Kevere, Laura; Bezborodovs, Nikita; Purvina, Santa; Rozentals, Guntis; Strautmanis, Jurgis; Viksna, Zane (2015-12-01). "Acute psychosis due to non-paraneoplastic anti-NMDA-receptor encephalitis in a teenage girl: Case report". PsyCh Journal. 4 (4): 226–230. ISSN 2046-0260. PMID 26663628. doi:10.1002/pchj.121. 
  39. ^ Gołab-Janowska, Monika; Nowacki, Przemysław (2011-01-01). "[Limbic encephalitis: a review of the literature]". Annales Academiae Medicae Stetinensis. 57 (3): 5–11. ISSN 1427-440X. PMID 23383541. 
  40. ^ Hacohen, Yael; Deiva, Kumaran; Pettingill, Phillipa; Waters, Patrick; Siddiqui, Ata; Chretien, Pascale; Menson, Esse; Lin, Jean-Pierre; Tardieu, Marc (2014-01-01). "N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse". Movement Disorders. 29 (1): 90–96. ISSN 1531-8257. PMID 24014096. doi:10.1002/mds.25626. 
  41. ^ Goldberg, Ethan M.; Titulaer, Maarten; de Blank, Peter M.; Sievert, Angela; Ryan, Nicole (2014-02-01). "Anti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature". Pediatric Neurology. 50 (2): 181–184. ISSN 1873-5150. PMID 24315538. doi:10.1016/j.pediatrneurol.2013.10.002. 
  42. ^ Höftberger, Romana; Armangue, Thaís; Leypoldt, Frank; Graus, Francesc; Dalmau, Josep (2013-08-01). "Clinical Neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-Daspartate receptor antibodies are part of the problem". Clinical Neuropathology. 32 (4): 251–254. ISSN 0722-5091. PMC 3749751Freely accessible. PMID 23806220. 
  43. ^
    B. Tatlı in 2016
    Sutcu, Murat; Akturk, Hacer; Somer, Ayper; Tatli, Burak; Torun, Selda Hancerli; Yıldız, Edibe Pembegul; Şık, Guntulu; Citak, Agop; Agacfidan, Ali (2015-07-16). "Role of Autoantibodies to N-Methyl-d-Aspartate (NMDA) Receptor in Relapsing Herpes Simplex Encephalitis: A Retrospective, One-Center Experience". Journal of Child Neurology. 31 (3): 345–50. ISSN 1708-8283. PMID 26184485. doi:10.1177/0883073815595079. 
  44. ^ Morvan, A (1890). "De la chorée fibrillaire". Gaz Hebd Mèd Chir. 27: 173–200. 
  45. ^ a b Isaac, H (1961). "A syndrome of continuous muscle-fibre activity.". J Neurol Neurosurg Psychiatry. 24: 219–325. 
  46. ^ Mertens, H-G (1 September 1965). "Neuromyotonie". Klin Wochenschr. 43 (17): 917–25. PMID 5863557. doi:10.1007/bf01712058. 
  47. ^ Davis, Newsom (1993). "Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review.". Brain. 116 (Pt 2): 453–69. PMID 8461975. doi:10.1093/brain/116.2.453. 
  48. ^ a b Shillito, P (1995). "Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerve". Ann Neurol. 38 (5): 714–22. PMID 7486862. doi:10.1002/ana.410380505. 
  49. ^ Hart, IK (1997). "Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia". Ann. Neurol. 41 (2): 238–46. PMID 9029073. doi:10.1002/ana.410410215. 
  50. ^ a b c d Maskery, Mark; Chhetri, Suresh K.; Dayanandan, Rejith; Gall, Claire; Emsley, Hedley C. A. (2016-01-01). "Morvan Syndrome". The Neurohospitalist. 6 (1): 32–35. ISSN 1941-8744. PMC 4680894Freely accessible. PMID 26740856. doi:10.1177/1941874415580597. 
  51. ^ Serratrice, G (1994). "What is left of Morvan's fibrillary chorea?". Rev Neurol. 150 (4): 257–65. PMID 7863176. 
  52. ^ Halbach, M (1987). "Neuromuscular, autonomic and central cholinergic hyperactivity associated with thymoma and acetylcholine receptor-binding antibody.". J. Neurol. 234 (6): 433–6. PMID 3655849. doi:10.1007/bf00314093. 
  53. ^ Madrid, A (1996). "Morvan's fibrillary chorea: remission after plasmapheresis.". J. Neurol. 243 (4): 350–3. PMID 8965109. doi:10.1007/bf00868410. 
  54. ^ Heidenreich, Fedor (1998). "Antibodies to ion-channel proteins in thymoma with myasthenia, neuromyotonia, and peripheral neuropathy". Neurology. 50 (5): 1483–1485. PMID 9596015. doi:10.1212/wnl.50.5.1483. 
  55. ^ Lee, EK (1998). "Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma". J Neurol Neurosurg Psychiatry. 65 (6): 857–862 doi:10.1136/jnnp.65.6.857. doi:10.1136/jnnp.65.6.857. 
  56. ^ Barber, PA (2000). "Morvan’s syndrome associated with voltage-gated K channel antibodies". Neurology. 54 (3): 771. doi:10.1212/wnl.54.3.771. 
  57. ^ a b c d e f Irani, Sarosh R.; Pettingill, Philippa; Kleopa, Kleopas A.; Schiza, Natasa; Waters, Patrick; Mazia, Claudio; Zuliani, Luigi; Watanabe, Osamu; Lang, Bethan (2012-08-01). "Morvan syndrome: clinical and serological observations in 29 cases". Annals of Neurology. 72 (2): 241–255. ISSN 1531-8249. PMID 22473710. doi:10.1002/ana.23577. 
  58. ^ Josephs, Keith A.; Silber, Michael H.; Fealey, Robert D.; Nippoldt, Todd B.; Auger, Raymond G.; Vernino, Steven (2004-12-01). "Neurophysiologic studies in Morvan syndrome". Journal of Clinical Neurophysiology. 21 (6): 440–445. ISSN 0736-0258. PMID 15622131. doi:10.1097/00004691-200411000-00008. 
  59. ^ Abou-Zeid, Elias; Boursoulian, Lana Jeradeh; Metzer, Walter S.; Gundogdu, Betul (2012-06-01). "Morvan syndrome: a case report and review of the literature". Journal of Clinical Neuromuscular Disease. 13 (4): 214–227. ISSN 1537-1611. PMID 22622167. doi:10.1097/CND.0b013e31822b1977. 
  60. ^ Ambrose, H. E.; Granerod, J.; Clewley, J. P.; Davies, N. W. S.; Keir, G.; Cunningham, R.; Zuckerman, M.; Mutton, K. J.; Ward, K. N. (2011-10-01). "Diagnostic Strategy Used To Establish Etiologies of Encephalitis in a Prospective Cohort of Patients in England▿". Journal of Clinical Microbiology. 49 (10): 3576–3583. ISSN 0095-1137. PMC 3187347Freely accessible. PMID 21865429. doi:10.1128/JCM.00862-11. 
  61. ^ Vitaliani, Roberta; Mason, Warren; Ances, Beau; Zwerdling, Theodore; Jiang, Zhilong; Dalmau, Josep (2005-10-01). "Paraneoplastic Encephalitis, Psychiatric Symptoms, and Hypoventilation in Ovarian Teratoma". Annals of Neurology. 58 (4): 594–604. ISSN 0364-5134. PMC 2245881Freely accessible. PMID 16178029. doi:10.1002/ana.20614. 
  62. ^ a b Dalmau, Josep; Tüzün, Erdem; Wu, Hai-yan; Masjuan, Jaime; Rossi, Jeffrey E.; Voloschin, Alfredo; Baehring, Joachim M.; Shimazaki, Haruo; Koide, Reiji (2007-01-01). "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma". Annals of Neurology. 61 (1): 25–36. ISSN 0364-5134. PMC 2430743Freely accessible. PMID 17262855. doi:10.1002/ana.21050. 
  63. ^ a b c d Barry, Helen; Byrne, Susan; Barrett, Elizabeth; Murphy, Kieran C.; Cotter, David R. (2015-02-01). "Anti-N-methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment". BJPsych Bulletin. 39 (1): 19–23. ISSN 2056-4694. PMC 4495821Freely accessible. PMID 26191419. doi:10.1192/pb.bp.113.045518. 
  64. ^ Granerod, Julia; Ambrose, Helen E.; Davies, Nicholas Ws; Clewley, Jonathan P.; Walsh, Amanda L.; Morgan, Dilys; Cunningham, Richard; Zuckerman, Mark; Mutton, Ken J. (2010-12-01). "Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study". The Lancet. Infectious Diseases. 10 (12): 835–844. ISSN 1474-4457. PMID 20952256. doi:10.1016/S1473-3099(10)70222-X. 
  65. ^ Gable, Mary S.; Sheriff, Heather; Dalmau, Josep; Tilley, Drake H.; Glaser, Carol A. (2012-04-01). "The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project". Clinical Infectious Diseases. 54 (7): 899–904. ISSN 1537-6591. PMC 3297648Freely accessible. PMID 22281844. doi:10.1093/cid/cir1038. 
  66. ^ Steiner, Johann; Walter, Martin; Glanz, Wenzel; Sarnyai, Zoltán; Bernstein, Hans-Gert; Vielhaber, Stefan; Kästner, Andrea; Skalej, Martin; Jordan, Wolfgang (2013-03-01). "Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis". JAMA psychiatry. 70 (3): 271–278. ISSN 2168-6238. PMID 23344076. doi:10.1001/2013.jamapsychiatry.86. 
  67. ^ Zandi, Michael S.; Irani, Sarosh R.; Lang, Bethan; Waters, Patrick; Jones, Peter B.; McKenna, Peter; Coles, Alasdair J.; Vincent, Angela; Lennox, Belinda R. (2011-04-01). "Disease-relevant autoantibodies in first episode schizophrenia". Journal of Neurology. 258 (4): 686–688. ISSN 0340-5354. PMC 3065649Freely accessible. PMID 20972895. doi:10.1007/s00415-010-5788-9. 
  68. ^ a b Dalmau,, J (2011). "Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis". The Lancet. Neurology. 10 (1): 63–74. PMC 3158385Freely accessible. PMID 21163445. doi:10.1016/s1474-4422(10)70253-2. 
  69. ^ a b Titulaer, Maarten J.; McCracken, Lindsey; Gabilondo, Iñigo; Armangué, Thaís; Glaser, Carol; Iizuka, Takahiro; Honig, Lawrence S.; Benseler, Susanne M.; Kawachi, Izumi (2013-02-01). "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study". The Lancet. Neurology. 12 (2): 157–165. ISSN 1474-4465. PMC 3563251Freely accessible. PMID 23290630. doi:10.1016/S1474-4422(12)70310-1. 
  70. ^ Shillito, Paul (1995). "Acquired neuromyotonia: Evidence for autoantibodies directed against K+ channels of peripheral nerves". Ann Neurol. 38 (5): 714–722. PMID 7486862. doi:10.1002/ana.410380505. 
  71. ^ Lai, Meizan; Huijbers, Maartje G. M.; Lancaster, Eric; Graus, Francesc; Bataller, Luis; Balice-Gordon, Rita; Cowell, John K.; Dalmau, Josep (2010-08-01). "Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series". The Lancet. Neurology. 9 (8): 776–785. ISSN 1474-4465. PMC 3086669Freely accessible. PMID 20580615. doi:10.1016/S1474-4422(10)70137-X. 
  72. ^ Irani, Sarosh R.; Alexander, Sian; Waters, Patrick; Kleopa, Kleopas A.; Pettingill, Philippa; Zuliani, Luigi; Peles, Elior; Buckley, Camilla; Lang, Bethan (2010-09-01). "Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia". Brain. 133 (9): 2734–2748. ISSN 1460-2156. PMC 2929337Freely accessible. PMID 20663977. doi:10.1093/brain/awq213. 
  73. ^ Klein, Christopher J.; Lennon, Vanda A.; Aston, Paula A.; McKeon, Andrew; O'Toole, Orna; Quek, Amy; Pittock, Sean J. (2013-02-01). "Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping". JAMA Neurology. 70 (2): 229–234. ISSN 2168-6157. PMC 3895328Freely accessible. PMID 23407760. doi:10.1001/jamaneurol.2013.592. 
  74. ^ Huda, S.; Wong, S. H.; Pettingill, P.; O'Connell, D.; Vincent, A.; Steiger, M. (2015-02-01). "An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre". Journal of Neurology. 262 (2): 418–424. ISSN 1432-1459. PMID 25428531. doi:10.1007/s00415-014-7588-0. 
  75. ^ a b c Paterson, Ross W.; Zandi, Michael S.; Armstrong, Richard; Vincent, Angela; Schott, Jonathan M. (2014-06-01). "Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre". Journal of Neurology, Neurosurgery, and Psychiatry. 85 (6): 625–630. ISSN 1468-330X. PMC 4451115Freely accessible. PMID 23757422. doi:10.1136/jnnp-2013-305218. 
  76. ^ a b c Irani, Sarosh R.; Michell, Andrew W.; Lang, Bethan; Pettingill, Philippa; Waters, Patrick; Johnson, Michael R.; Schott, Jonathan M.; Armstrong, Richard J. E.; S Zagami, Alessandro (2011-05-01). "Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis". Annals of Neurology. 69 (5): 892–900. ISSN 1531-8249. PMID 21416487. doi:10.1002/ana.22307. 
  77. ^ Andrade, Danielle M.; Tai, Peter; Dalmau, Josep; Wennberg, Richard (2011-04-12). "Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?". Neurology. 76 (15): 1355–1357. ISSN 1526-632X. PMC 3090064Freely accessible. PMID 21482953. doi:10.1212/WNL.0b013e3182152808. 
  78. ^ Quek, Amy M. L.; Britton, Jeffrey W.; McKeon, Andrew; So, Elson; Lennon, Vanda A.; Shin, Cheolsu; Klein, Christopher; Watson, Robert E.; Kotsenas, Amy L. (2012-05-01). "Autoimmune epilepsy: clinical characteristics and response to immunotherapy". Archives of Neurology. 69 (5): 582–593. ISSN 1538-3687. PMC 3601373Freely accessible. PMID 22451162. doi:10.1001/archneurol.2011.2985. 
  79. ^ Boronat, Anna; Gelfand, Jeffrey M.; Gresa-Arribas, Nuria; Jeong, Hyo-Young; Walsh, Michael; Roberts, Kirk; Martinez-Hernandez, Eugenia; Rosenfeld, Myrna R.; Balice-Gordon, Rita (2013-01-01). "Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels". Annals of Neurology. 73 (1): 120–128. ISSN 1531-8249. PMC 3563722Freely accessible. PMID 23225603. doi:10.1002/ana.23756. 
  80. ^ Balint, Bettina; Jarius, Sven; Nagel, Simon; Haberkorn, Uwe; Probst, Christian; Blöcker, Inga Madeleine; Bahtz, Ramona; Komorowski, Lars; Stöcker, Winfried (2014-04-29). "Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies". Neurology. 82 (17): 1521–1528. ISSN 1526-632X. PMID 24696508. doi:10.1212/WNL.0000000000000372. 
  81. ^ a b c d e Tan, K. M.; Lennon, V. A.; Klein, C. J.; Boeve, B. F.; Pittock, S. J. (2008-05-13). "Clinical spectrum of voltage-gated potassium channel autoimmunity". Neurology. 70 (20): 1883–1890. ISSN 1526-632X. PMID 18474843. doi:10.1212/01.wnl.0000312275.04260.a0. 
  82. ^ Lai, Meizan; Hughes, Ethan G.; Peng, Xiaoyu; Zhou, Lei; Gleichman, Amy J.; Shu, Huidy; Matà, Sabrina; Kremens, Daniel; Vitaliani, Roberta (2009-04-01). "AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location". Annals of Neurology. 65 (4): 424–434. ISSN 1531-8249. PMC 2677127Freely accessible. PMID 19338055. doi:10.1002/ana.21589. 
  83. ^ Höftberger, R (2015). "Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients". Neurology. 84 (24): 2403–2412. PMC 4478035Freely accessible. PMID 25979696. doi:10.1212/WNL.0000000000001682. 
  84. ^ Carvajal-Gonzalez, A (2014). "Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes". Brain. 137 (Pt 8): 2178–2192. PMC 4107739Freely accessible. PMID 24951641. doi:10.1093/brain/awu142. 
  85. ^ a b Ekizoglu, Esme; Tuzun, Erdem; Woodhall, Mark; Lang, Bethan; Jacobson, Leslie; Icoz, Sema; Bebek, Nerses; Gurses, Candan; Gokyigit, Aysen (2014-03-01). "Investigation of neuronal autoantibodies in two different focal epilepsy syndromes". Epilepsia. 55 (3): 414–422. ISSN 1528-1167. PMID 24502404. doi:10.1111/epi.12528. 
  86. ^ Martinez-Hernandez, Eugenia; Sepulveda, Maria; Rostásy, Kevin; Höftberger, Romana; Graus, Francesc; Harvey, Robert J.; Saiz, Albert; Dalmau, Josep (2015-02-01). "Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis". JAMA Neurology. 72 (2): 187–193. ISSN 2168-6157. PMC 4836943Freely accessible. PMID 25506781. doi:10.1001/jamaneurol.2014.3602. 
  87. ^ Dale, R. C.; Church, A. J.; Cardoso, F.; Goddard, E.; Cox, T. C.; Chong, W. K.; Williams, A.; Klein, N. J.; Neville, B. G. (2001-11-01). "Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies". Annals of Neurology. 50 (5): 588–595. ISSN 0364-5134. PMID 11706964. doi:10.1002/ana.1250. 
  88. ^ Kirvan, Christine A.; Swedo, Susan E.; Snider, Lisa A.; Cunningham, Madeleine W. (2006-10-01). "Antibody-mediated neuronal cell signaling in behavior and movement disorders". Journal of Neuroimmunology. 179 (1–2): 173–179. ISSN 0165-5728. PMID 16875742. doi:10.1016/j.jneuroim.2006.06.017. 
  89. ^ Martino, Davide; Dale, Russell C.; Gilbert, Donald L.; Giovannoni, Gavin; Leckman, James F. (2009-07-15). "Immunopathogenic Mechanisms in Tourette Syndrome: A Critical Review". Movement Disorders. 24 (9): 1267–1279. ISSN 0885-3185. PMC 3972005Freely accessible. PMID 19353683. doi:10.1002/mds.22504. 
  90. ^ a b c d e Dale, Russell C.; Merheb, Vera; Pillai, Sekhar; Wang, Dongwei; Cantrill, Laurence; Murphy, Tanya K.; Ben-Pazi, Hilla; Varadkar, Sophia; Aumann, Tim D. (2012-11-01). "Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders". Brain. 135 (Pt 11): 3453–3468. ISSN 1460-2156. PMID 23065479. doi:10.1093/brain/aws256. 
  91. ^ Nikolaus, Susanne; Antke, Christina; Müller, Hans-Wilhelm (2009-12-01). "In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia". Behavioural Brain Research. 204 (1): 1–31. ISSN 1872-7549. PMID 19523490. doi:10.1016/j.bbr.2009.06.008. 
  92. ^ Klein, C.; Brin, M. F.; Kramer, P.; Sena-Esteves, M.; de Leon, D.; Doheny, D.; Bressman, S.; Fahn, S.; Breakefield, X. O. (1999-04-27). "Association of a missense change in the D2 dopamine receptor with myoclonus dystonia". Proceedings of the National Academy of Sciences of the United States of America. 96 (9): 5173–5176. Bibcode:1999PNAS...96.5173K. ISSN 0027-8424. PMC 21836Freely accessible. PMID 10220438. doi:10.1073/pnas.96.9.5173. 
  93. ^ a b Petit-Pedrol, Mar; Armangue, Thaís; Peng, Xiaoyu; Bataller, Luis; Cellucci, Tania; Davis, Rebecca; McCracken, Lindsey; Martinez-Hernandez, Eugenia; Mason, Warren P. (2014-03-01). "Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies". The Lancet. Neurology. 13 (3): 276–286. ISSN 1474-4465. PMC 4838043Freely accessible. PMID 24462240. doi:10.1016/S1474-4422(13)70299-0. 
  94. ^ a b c d e f Pettingill, Philippa; Kramer, Holger B.; Coebergh, Jan Adriaan; Pettingill, Rosie; Maxwell, Susan; Nibber, Anjan; Malaspina, Andrea; Jacob, Anu; Irani, Sarosh R. (2015-03-24). "Antibodies to GABAA receptor α1 and γ2 subunits: clinical and serologic characterization". Neurology. 84 (12): 1233–1241. ISSN 1526-632X. PMC 4366091Freely accessible. PMID 25636713. doi:10.1212/WNL.0000000000001326. 
  95. ^ Ariño, Helena; Höftberger, Romana; Gresa-Arribas, Nuria; Martínez-Hernández, Eugenia; Armangue, Thaís; Kruer, Michael C.; Arpa, Javier; Domingo, Julio; Rojc, Bojan (2015-08-01). "Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies". JAMA Neurology. 72 (8): 874–881. ISSN 2168-6157. PMC 4838033Freely accessible. PMID 26099072. doi:10.1001/jamaneurol.2015.0749. 
  96. ^ a b c Kim, Tae-Joon; Lee, Soon-Tae; Shin, Jung-Won; Moon, Jangsup; Lim, Jung-Ah; Byun, Jung-Ick; Shin, Yong-Won; Lee, Keon-Joo; Jung, Keun-Hwa (2014-05-15). "Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis". Journal of Neuroimmunology. 270 (1–2): 45–50. ISSN 1872-8421. PMID 24662003. doi:10.1016/j.jneuroim.2014.02.011. 
  97. ^ a b c Höftberger, Romana; Titulaer, Maarten J.; Sabater, Lidia; Dome, Balazs; Rózsás, Anita; Hegedus, Balazs; Hoda, Mir Alireza; Laszlo, Viktoria; Ankersmit, Hendrik Jan (2013-10-22). "Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients". Neurology. 81 (17): 1500–1506. ISSN 1526-632X. PMC 3888170Freely accessible. PMID 24068784. doi:10.1212/WNL.0b013e3182a9585f. 
  98. ^ Sillevis Smitt, P.; Kinoshita, A.; De Leeuw, B.; Moll, W.; Coesmans, M.; Jaarsma, D.; Henzen-Logmans, S.; Vecht, C.; De Zeeuw, C. (2000-01-06). "Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor". The New England Journal of Medicine. 342 (1): 21–27. ISSN 0028-4793. PMID 10620645. doi:10.1056/NEJM200001063420104. 
  99. ^ Marignier, Romain; Chenevier, Florian; Rogemond, Veronique; Sillevis Smitt, Peter; Renoux, Christel; Cavillon, Gaëlle; Androdias, Geraldine; Vukusic, Sandra; Graus, Francesc (2010-05-01). "Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease?". Archives of Neurology. 67 (5): 627–630. ISSN 1538-3687. PMID 20457964. doi:10.1001/archneurol.2010.51. 
  100. ^ Carr, I (1982). "The Ophelia syndrome: memory loss in Hodgkin's disease". Lancet. 1 (8276): 844–5. PMID 6122069. doi:10.1016/s0140-6736(82)91887-6. 
  101. ^ a b Lancaster, E.; Martinez-Hernandez, E.; Titulaer, M. J.; Boulos, M.; Weaver, S.; Antoine, J.-C.; Liebers, E.; Kornblum, C.; Bien, C. G. (2011-11-01). "Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome". Neurology. 77 (18): 1698–1701. ISSN 1526-632X. PMC 3208954Freely accessible. PMID 22013185. doi:10.1212/WNL.0b013e3182364a44. 
  102. ^ Sabater, Lidia; Gaig, Carles; Gelpi, Ellen; Bataller, Luis; Lewerenz, Jan; Torres-Vega, Estefanía; Contreras, Angeles; Giometto, Bruno; Compta, Yaroslau (2014-06-01). "A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study". The Lancet. Neurology. 13 (6): 575–586. ISSN 1474-4465. PMC 4104022Freely accessible. PMID 24703753. doi:10.1016/S1474-4422(14)70051-1. 

External links[edit]